Abstract
Get full access to this article
View all access options for this article.
References
1.
Barter P.J.
Caulfield M.
Eriksson M.
Effects of torcetrapib in patients at high risk for coronary events . N Engl J Med. 2007 ; 357 : 2109 –2122 .
2.
Everett B.M.
Smith R.J.
Hiatt W.R.
Reducing LDL with PCSK9 inhibitors – The clinical benefit of lipid drugs . N Engl J Med. 2015 ; 373 : 1588 –1591 .
3.Afstyla (antihemophilic factor (recombinant), single chain) [prescribing information]. Kankakee, IL : CSL Behring LLC ; May 2016 . http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM503560.pdf
4.Cabometyx (cabozantinib) [prescribing information]. South San Francisco, CA : Exelixis, Inc. ; April 2016 . http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208692s000lbl.pdf
5.Cinqair (reslizumab) [prescribing information] Frazer, PA : Teva Respiratory, LLC ; March 2016 . http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf
6.Descovy (emtricitabine/tenofovir alafenamide) [prescribing information]. Foster City, CA : Gilead Sciences, Inc. ; April 2016 . http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208215s000lbl.pdf
7.Clinical Guidelines Portal: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents . ADISinfo website. Published January 28, 2016. https://aid-sinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/9/treatment-goals. Accessed July 11, 2016.
8.Evomela (melphalan) [prescribing information]. Irvine, CA : Spectrum Pharmaceuticals ; March 2016 . http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207155s000lbl.pdf
9.Idelvion [Coagulation Factor IX (Recombinant), Albumin Fusion Protein] [prescribing information]. Kankakee, IL : CSL Behring LLC ; March 2016 . http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM489301.pdf
10.Inflectra (infliximab-dyyb) [prescribing information]. Lake Forest, IL : Celltrion, Inc. ; April 2016 . http://www.accessdata.fda.gov/drugsatfda_docs/labeV2016/125544s000lbl.pdf
11.Kovaltry [Antihemophilic Factor (Recombinant)] [prescribing information]. Whippany, NJ : Bayer HealthCare LLC; March 2016 . http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM491118.pdf
12.Nuplazid (pimavanserin) [prescribing information]. San Diego, CA : Acadia Pharmaceuticals, Inc. ; April 2016 . http://www.accessdata.fda.gov/drugsatfda_docs/label/20167207318lbl.pdf
13.Ocaliva (obeticholic acid) [prescribing information] New York : Intercept Pharmaceuticals ; May 2016 . http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207999s000lbl.pdf
14.Odefsey (emtricitabine/rilpivirine hydrochloride/tenofovir alafenamide fumarate) [prescribing information]. Foster City, CA : Gilead Sciences, Inc. ; March 2016 . http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208351s000lbl.pdf
15.Taltz (ixekizumab) [prescribing information]. Indianapolis, IN : Eli Lilly and Co. ; March 2016 . http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf
16.Tecentriq (atezolizumab) [prescribing information]. South San Francisco, CA : Genentech, Inc. ; May 2016 . http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761034Origls000lbl.pdf
17.Venclexta (venetoclax) [prescribing information]. North Chicago, IL : AbbVie, Inc. ; April 2016 . http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf
18.Zinbryta (daclizumab) [prescribing information]. Cambridge, MA : Biogen; May 2016 . http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761029s000lbl.pdf